<DOC>
	<DOC>NCT00615108</DOC>
	<brief_summary>The purpose of this observational study is to survey the safety and effectiveness of the product under the real condition of usual practice in Taiwanese hypertensive patients. During the 8-week observation, the safety profiles and the clinical evaluation in between doses through blood pressure (BP) measurement for overall effectiveness of telmisartan therapy will be concluded.</brief_summary>
	<brief_title>Nice Morning- Safety and Efficacy Observational Study of Telmisartan in Hypertensive Patients in Multicenters</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<criteria>1. Male or female. 2. Aged 20 to 80 years old. 3. Patients meet one of following two criteria: 1. Adult essential hypertensive either newly diagnosed and untreated, or previously treated and uncontrolled patients; sitting blood pressure: systolic blood pressure (BP) &gt; 140 mmHg but &lt; 180 mmHg, and/or diastolic BP &gt; 90 mmHg but &lt; 110 mmHg). 2. Patients who are assessed to benefit from the intake of angiotensin II receptor blocker (ARB) monotherapy or as addon medication. 1. Patients with contraindications to telmisartan use (as per the Micardis® Tablets package insert). 2. Known hypersensitivity to the active ingredient or to any of the excipients of Micardis® Tablets. 3. Any other clinical condition which, in the opinion of the attending physician, would not allow safe administration of the study medications.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>